Format

Send to

Choose Destination
Kidney Int Suppl. 1999 Jul;71:S251-3.

Lipoprotein(a) is a predictor for cardiovascular mortality of hemodialysis patients.

Author information

1
Kidney Center of Shinraku-en Hospital, Niigata University, School of Medicine, Japan. WG8Y-KUD@asahi-net.or.jp

Abstract

BACKGROUND:

Although hemodialysis (HD) patients have been associated with elevations in serum lipoprotein(a) [Lp(a)] levels, relatively little has been published on the link between Lp(a) and the risk for atherosclerotic cardiovascular death in HD patients.

METHODS:

Lipoprotein(a) was measured in 390 HD patients. The relationship between Lp(a) and mortality (overall and cardiovascular) was determined during 28 months of prospective follow-up.

RESULTS:

Hemodialysis patients demonstrated Lp(a) concentrations that were approximately two times as high as that of healthy controls (median, 16 vs. 8 mg/dl, P < 0.001; mean, 22.9 vs. 12.1 mg/dl, P < 0.01). Lp(a) showed a significant correlation between albumin, total cholesterol, low-density lipoprotein cholesterol, and C-reactive protein. The high-Lp(a) group [Lp(a) > or = 30 mg/dl] showed significantly higher mortality than the low-Lp(a) group [Lp(a) < 30 mg/dl] in a Kaplan-Meier survival analysis (P < 0.05). Multiple logistic regression analysis demonstrated albumin, age, and diabetic state as significant risk factors for overall death. However, if confined to atherosclerotic cardiovascular death, Lp(a) (P < 0.01), age, and diabetic state were the only independent contributors.

CONCLUSIONS:

Lp(a) is an independent risk factor for atherosclerotic cardiovascular death in Japanese patients receiving chronic dialysis therapy.

PMID:
10412791
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center